FGD3 and sarcoma: In summary, the statistically significant hits for FGD3 mRNA (z-score) as a continuous variable in a Cox regression model included head and neck squamous cell carcinoma (HR, 0.72; 95% CI, 0.63 to 0.81; P = 5.99E-7), lung adenocarcinoma (HR, 0.78; 95% CI, 0.68 to 0.89; P = 3.32E-4), cervical squamous cell carcinoma and endocervical adenocarcinoma (HR, 0.69; 95% CI, 0.54 to 0.87; P = .002), sarcoma (HR, 0.73; 95% CI, 0.60 to 0.90; P = .003), invasive breast carcinoma (HR, 0.82; 95% CI, 0.70 to 0.96; P = .015), and urothelial bladder carcinoma (HR, 0.85; 95% CI, 0.73 to 0.99; P = .033).